Ginkgo Bioworks Holdings Inc-A 2025年季度报告

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _________________ to _________________ ______________________________________________ GINKGO BIOWORKS HOLDINGS, INC.(Exact Name of Registrant as Specified in its Charter) Delaware87-2652913(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.) This report includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and assumptions of the management of Ginkgo. Although Ginkgo believes that its plans, intentions and expectations reflected in orsuggested by these forward-looking statements are reasonable, Ginkgo cannot assure you that it will achieve or realize these plans, or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “intends” or similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are notlimited to, statements about: •factors relating to the business, operations and financial performance of Ginkgo, including: Ginkgo’s ability to develop and expand its offerings; the anticipated growth of Ginkgo’s biomonitoring and bioinformatics services and the relative value of the serviceson Ginkgo’s future Biosecurity revenue; the scope and timing of Ginkgo’s partnerships around the world;Ginkgo’s ability to effectively manage its organizational changes, including its restructuring actions and facilityconsolidations commenced in 2024, and related impacts on Ginkgo’s financial performance; ◦ the potential acquisition and integration of companies, assets or intellectual property that advance Ginkgo’s objectives; andcosts required to maintain, expand and protect Ginkgo’s intellectual property. expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others:•intense competition and competitive pressures from other companies worldwide in the industries in which Ginkgo operates; •rapidly changing technology and extensive competition in the synthetic biology industry that could make the products and processes Ginkgo is developing obsolete or non-competitive unless it continues to collaborate on the development of new andimproved products and processes and pursue new market opportunities;•Ginkgo’s ability to convert potential customers from “on prem” research and development (“R&D”) to outsourced services,Ginkgo’s reliance on its customers to develop, produce and manufacture products using the engineered cells and/orbiomanufacturing processes that Ginkgo develops and Ginkgo’s ability to accurately predict customer demand, including •market conditions and global and economic factors beyond Ginkgo’s control, including initiatives undertaken by the U.S.government in the biotechnology sector, the frequency and scale of biological risks and threats, and the future potential and •other factors in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Change in fair value of warrant liabilitiesChange in fair value of contingent consideration Non-cash in-process research and development Other non-cash activity149Changes in operating assets and liabilities:Accounts receivable ($(291) and $372 from related parties)(4,693)Prepaid expenses and other current assets462Operating lease right-of-use assets3,675Other non-current assets(167) Net cash used in operating activities(51,521)Cash flows from investing activities:Purchases of marketable debt securities(191,182) Net cash used in investing activities Cash flows from financing activities:Proceeds from exercise of stock options—Principal payments on finance leases(207) Cash and cash equivalents, beginning of periodRestricted cash, beginning of period Cash, cash equivalents and restricted cash, beginning of period Restricted cash, end of periodCash, cash equivalents and restricted cash, end of period The accompanying notes are an integral part of these condensed consolidated financial statements. 1.Basis of Presentation and Summary of Significant Accounting Policies The mission of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) is to make biology easier to engineer. The Companyprovides biological research and development services for customers across multiple markets and industries. Since inception, the Company has devoted its efforts to improving its platform for programming cells to enable customers to leverage biology to createimpactful products across a range of industries. The Company’s platform comprises (i) equipment, robotic automation, software, datapipelines and tools, and standard operating procedures for high throughput cell engineering, fermentation, and analytics (referred tocollectively as the “Found